David W Meyer

发表

Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system.

Martha Anderson, P. Burke, P. Senter, 2009, Bioorganic & medicinal chemistry letters.

Development of Novel Antibody–Camptothecin Conjugates

Kim K. Emmerton, P. Senter, Lauren Farr, 2020, Molecular Cancer Therapeutics.

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

I. Bernstein, P. Burke, R. Walter, 2013, Blood.

An in vitro assay using cultured Kupffer cells can predict the impact of drug conjugation on in vivo antibody pharmacokinetics.

Joseph Z. Hamilton, J. Hunter, N. Okeley, 2020, Molecular pharmaceutics.

Contribution of Nontarget Cells to the Disposition, Antitumor Activity, and Antigen-Independent Toxicity of Antibody–Drug Conjugates

R. Lyon, Fu Li, David W Meyer, 2021 .

Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody–Drug Conjugates

J. Nix, A. Waight, P. Senter, 2018, Molecular Cancer Therapeutics.

A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.

P. Burke, P. Senter, D. Sussman, 2013, Bioconjugate chemistry.

Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability

P. Carter, D. Benjamin, S. Alley, 2018, Protein engineering, design & selection : PEDS.

Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues.

D. Kroll, P. Burke, P. Senter, 2009, Bioconjugate chemistry.

Novel peptide linkers for highly potent antibody-auristatin conjugate.

P. Senter, S. Doronina, Martha E. Anderson, 2008, Bioconjugate chemistry.